(VIANEWS) – The Market ended the session with ADOCIA (ADOC.PA) jumping 28.75% to €4.12 on Monday, after three sequential sessions in a row of gains. CAC 40 rose 0.11% to €7,440.91, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
ADOCIA’s last close was €3.20, 50.46% below its 52-week high of €6.46.
About ADOCIA
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes bi-hormonal products, which include BioChaperone AsPram, which is a combination of rapid insulin aspart with pramlintide; and BioChaperone Glargine Liraglutidea, which is a fixed combination of insulin glargine with an analogue of the GLP-1 receptor. In addition, the company's preclinical pipeline includes multihormonal products for the treatment of obesity, including BioChaperone GluExe, which is a combination of glucagon and exenatide; PramExe, which is a combination of pramlintide and exenatide; and BioChaperone PramGluExe, which is a triple combination of pramlintide, glucagon and exenatide. It has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The company was incorporated in 2005 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-1.22.
Revenue Growth
Year-on-year quarterly revenue growth grew by 312.1%, now sitting on 13.95M for the twelve trailing months.
Volatility
ADOCIA’s last week, last month’s, and last quarter’s current intraday variation average was 2.97%, 0.41%, and 2.36%.
ADOCIA’s highest amplitude of average volatility was 3.86% (last week), 2.24% (last month), and 2.36% (last quarter).
Yearly Top and Bottom Value
ADOCIA’s stock is valued at €4.12 at 22:30 EST, way under its 52-week high of €6.46 and way higher than its 52-week low of €2.80.
Moving Average
ADOCIA’s worth is way above its 50-day moving average of €3.58 and above its 200-day moving average of €3.96.
More news about ADOCIA (ADOC.PA).
